Valence8 US’s Vir Biotechnology VIR Stock Holding History

Valence8 US’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-33,650	Closed	-$252K	–	58
2024 Q3	$252K	Buy	+33,650	New	+$292K	0.1%	39

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Valence8 US's VIR Position: Q4 2024 in Review

Valence8 US sold out of Vir Biotechnology (VIR) in Q4 2024, closing a stake of 33,650 shares — an estimated $252K sold.

Valence8 US first reported a position in VIR in Q3 2024 and held it in 1 quarter. The position peaked at $252K in Q3 2024. 208 funds tracked by Wall St. Rank hold VIR as of Q4 2024.

Valence8 US reported no remaining Vir Biotechnology position as of Q4 2024 after selling out during the quarter.
Valence8 US sold 33,650 Vir Biotechnology shares in Q4 2024, an estimated $252K.
Valence8 US first reported a position in Vir Biotechnology in Q3 2024 and held it in 1 quarter.
Valence8 US's Vir Biotechnology position peaked at $252K in Q3 2024.
208 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2024.

Based on Valence8 US's 13F filing for Q4 2024, filed 12 Feb 2025.